Physician profile
Rafael Jimenez
NPI 1568493443
$5,068.56
in general payments reported to CMS, 2019-2025
32 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $535 · 2021: $1,076 · 2022: $1,001 · 2023: $689 · 2024: $352 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $944.34 | 2019-2024 | Xarelto |
| Abiomed | $812.94 | 2019-2021 | |
| Abbott Laboratories | $392.55 | 2019-2022 | |
| Pfizer INC. | $332.64 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $261.94 | 2021-2024 | Verquvo |
| Astellas Pharma US INC | $221.65 | 2020-2022 | |
| Irhythm Technologies, INC. | $215.49 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Astrazeneca Pharmaceuticals LP | $206.43 | 2019-2024 | Farxiga |
| Medtronic, INC. | $177.54 | 2021 | |
| Amgen INC. | $171.10 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $163.35 | 2019-2025 | |
| Boston Scientific Corporation | $147.11 | 2019 | |
| Impulse Dynamics (USA) INC. | $133.16 | 2022 | |
| Amarin Pharma, INC. | $127.71 | 2019-2021 | |
| Gilead Sciences, INC. | $125.70 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.60 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $88.60 | 2022-2025 | Camzyos, Eliquis |
| Bardy Diagnostics, INC. | $79.50 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.84 | 2019-2023 | Jardiance |
| Baxter Healthcare | $38.74 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Novo Nordisk INC | $37.72 | 2022-2023 | Ozempic |
| Medtronic Vascular, INC. | $28.27 | 2020 | |
| Edwards Lifesciences Corporation | $27.59 | 2022 | |
| Terumo Medical Corporation | $25.43 | 2023 | Heartrail |
| Scpharmaceuticals INC. | $25.34 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $24.96 | 2023 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $23.54 | 2023 | Inpefa |
| Inspire Medical Systems, INC. | $21.10 | 2025 | Inspire |
| Daiichi Sankyo INC. | $20.20 | 2023 | Injectafer |
| Cvrx, INC. | $18.44 | 2024 | Barostim Neo System |
| Glaxosmithkline, LLC. | $17.94 | 2025 | Shingrix, Arexvy |
| Cleerly, INC. | $13.10 | 2024 | Cleerly Labs, Cleerly Ischemia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.